{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.01","value":"-4.1"},{"groupId":"OG001","spread":"15.95","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"Cycle 3 Day 1 (C3 D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.73","value":"-2.4"},{"groupId":"OG001","spread":"17.13","value":"2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"C5 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.04","value":"-2.1"},{"groupId":"OG001","spread":"18.63","value":"-0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"title":"C7 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.75","value":"-1.8"},{"groupId":"OG001","spread":"18.88","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.32","value":"0.0"},{"groupId":"OG001","spread":"14.60","value":"6.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Extension Phase C1 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.68","value":"2.0"},{"groupId":"OG001","spread":"26.86","value":"-3.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Extension Phase C3 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.40","value":"0.8"},{"groupId":"OG001","spread":"20.04","value":"0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Extension Phase C5 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.03","value":"-0.5"},{"groupId":"OG001","spread":"20.87","value":"3.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Extension Phase C7 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.42","value":"-2.4"},{"groupId":"OG001","spread":"19.75","value":"11.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Extension Phase C9 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.53","value":"-1.8"},{"groupId":"OG001","spread":"24.47","value":"4.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Extension Phase C11 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.84","value":"-2.6"},{"groupId":"OG001","spread":"24.15","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Extension Phase C13 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.27","value":"3.1"},{"groupId":"OG001","spread":"27.26","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Extension Phase C15 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.03","value":"-0.6"},{"groupId":"OG001","spread":"26.79","value":"13.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Extension Phase C17 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.78","value":"-1.6"},{"groupId":"OG001","spread":"14.43","value":"-16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Extension Phase C19 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.32","value":"3.1"},{"groupId":"OG001","spread":"17.68","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Extension Phase C21 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.84","value":"0.9"},{"comment":"No standard deviation could be determined because a single participant was analyzed","groupId":"OG001","spread":"NA","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Extension Phase C23 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.15","value":"-2.0"},{"comment":"No standard deviation could be determined because a single participant was analyzed","groupId":"OG001","spread":"NA","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Extension Phase C25 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.40","value":"2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C27 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.12","value":"2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C29 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.93","value":"-0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C31 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.41","value":"-1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C33 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.33","value":"3.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C35 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.04","value":"0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C37 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.63","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C39 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.11","value":"6.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C41 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.29","value":"4.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C43 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.24","value":"-2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C45 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.08","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C47 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.40","value":"-3.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C49 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.33","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C51 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.76","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C53 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.35","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C55 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.89","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C57 D1"},{"categories":[{"measurements":[{"comment":"No standard deviation could be determined because a single participant was analyzed","groupId":"OG000","spread":"NA","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Extension Phase C59 D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.97","value":"-9.2"},{"groupId":"OG001","spread":"23.07","value":"-0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"The EORTC questionnaire is a validated health-related quality of life (HRQoL) measure applicable to participants with any cancer diagnosis. Version 3.0 of the questionnaire was used in the study.\n\nIt is composed of 30 items that address 15 domains, including one global health status, functional domains, and symptom domains. Domain scores are transformed to a 0 to 100 scale, where higher scores on the global quality of life score indicate better function. As such, a positive change from Baseline score indicates an improvement in quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All treated participants who completed the EORTC QLQ-C30 assessment at baseline and at least one post-baseline assessment visit.","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 3, Day 1 (C3 D1), C5 D1, C7 D1, Week 25, every other cycle during extension phase (C1 D1, C3 D1, C5 D1, etc. up to C59 D1) and end of treatment. Each cycle is composed of 21 days.","title":"Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Quality of Life Score","type":"SECONDARY","unitOfMeasure":"Score on a scale"}